Industry / South Korea

GlaxoSmithKline Acquires A Stake In Dong-A Pharmaceuticals

May 2010 | Industry Trend Analysis

Printable version
Bookmark

BMI Core View: Deals between drugmakers in emerging markets will become more

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Regional Risks Affecting Company Revenues

Industry BMI View: Western Europe remains attractive to innovative drugmakers: per capita spending is high, there is a sizeable pensionable population and regulations are transparent. BMI believes these factors...

January 2012

Western Europe To Remain A Prime Clinical Research Destination

Industry BMI Core View: Governments in developed states need to work to maintain the countries' long-term attractiveness as sites for clinical trials, especially as the cost of conducting clinical research is forecast...

December 2011

Pfizer Tops Inaugural Pharmaceutical Emerging Markets Sales Index

Industry Compared with other drugmakers, Pfizer generates the most sales in non-traditional markets, according to BMI's inaugural Pharmaceutical Emerging Markets Sales Index (PEMSI). The New York City-based firm...

November 2009

Quest Receives Approval For A(H1N1) Test

Industry Medical devices company Quest Diagnostics' Simplexa influenza A H1N1 (2009) test has been CE-approved and is now available as a test kit for distribution to 35 countries in Europe. BMI believes the approval...

November 2009

The WHO Awards Prequalification For Global Use Of GlaxoSmithKline's Pneumococcal Vaccine

Industry The World Health Organization (WHO) has awarded prequalification for global use to Synflorix, GlaxoSmithKline (GSK)'s pneumococcal conjugate vaccine. Pneumococcal disease describes infections caused...

November 2009